Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.66 +0.84 (+0.94%)
Streaming Delayed Price Updated: 1:18 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
74 75 Next >
News headline image
US Manufacturing Hits 18-Month High, China's Growth Could Trigger Deflation And More: Economics Weekly Roundup ↗
This week's top stories highlight significant developments, including the U.S. manufacturing sector reaching an 18-month high, potential deflation from China's manufacturing growth, a robust U.S. labor... 
Via Benzinga
Topics Economy
News headline image
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors
From Daiichi Sankyo
Via Business Wire
News headline image
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
From AstraZeneca
Via Business Wire
News headline image
A Closer Look at AstraZeneca's Options Market Dynamics ↗
 
Via Benzinga
News headline image
New Hope for Aggressive Lung Cancer: AstraZeneca's Imfinzi Shows Promising Results in Phase 3 Trial ↗
High-level results of AstraZeneca's ADRIATIC Phase 3 trial on Imfinzi monotherapy & Imfinzi plus Imjudo for limited-stage small cell lung cancer. Statistically significant OS & PFS improvement shown... 
Via Benzinga
News headline image
IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race ↗
AstraZeneca's CEO Pascal Soriot celebrates hitting a $45 billion sales target set a decade ago despite initial skepticism. Investor confidence remains a challenge amid stagnant shares and concerns over... 
Via Benzinga
News headline image
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
From AstraZeneca
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH
From Alexion
Via Business Wire
News headline image
7 Blue-Chip Stocks That Will Outperform the Dow in the 5 Five Years ↗
These are the blue-chip stocks to outperform Dow in the next five years and represents companies with growth and cash flow visibility. 
Via InvestorPlace
Topics Stocks
News headline image
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run ↗
Invest in stability, dividends, and growth with these three accomplished real estate operators. 
Via The Motley Fool
News headline image
What's Going On European Pharma Giant AstraZeneca Stock On Wednesday? ↗
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca... 
Via Benzinga
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
Via AB Newswire
Topics Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)
From Alexion
Via Business Wire
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
Via AB Newswire
Topics Artificial Intelligence Intellectual Property
News headline image
EXCLUSIVE: 2024 Witnesses Increase In Biotech Initial Public Offerings ↗
Dr. Laura Chico, Senior VP at Wedbush, is optimistic about 2024 biotech IPO market and M&A trends. Election year may affect performance. 
Via Benzinga
Topics Initial Public Offering
News headline image
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study ↗
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression. 
Via Benzinga
News headline image
Senator Bernie Sanders Applauds GSK's Move To Cap Inhaler Costs At $35 Per Month ↗
GSK caps asthma and COPD medicine costs at $35/month, effective Jan 1, 2025. Includes Advair, Breo, Ventolin. Follows AstraZeneca's suit for their respiratory medicines. Sanders applauds move amid... 
Via Benzinga
News headline image
3 Stagnating Blue-Chip Stocks Ready to Awaken and Soar ↗
These are the stagnating blue-chip stocks to buy at undervalued levels, as they represent fundamentally strong ideas with healthy cash flows. 
Via InvestorPlace
News headline image
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform ↗
Unlock potential with Voyager Therapeutics as HC Wainwright initiates coverage highlights its TRACER capsid platform, promising CNS-targeted gene therapies and strategic partnerships driving long-term... 
Via Benzinga
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Fusion Pharma Stock Nearly Doubles After Scoring $2 Billion AstraZeneca Takeover ↗
The company is working on radiopharmaceuticals treatments for cancer. 
Via Investor's Business Daily
News headline image
Why Is Fusion Pharmaceuticals (FUSN) Stock Up 101% Today? ↗
Fusion Pharmaceuticals stock is rising higher on Tuesday as AstraZeneca agrees to acquire FUSN for $21 per share with a CVR of $3. 
Via InvestorPlace
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Pre-market stock movers are worth diving into on Tuesday as we check out all of the hottest news worth reading about this morning! 
Via InvestorPlace
News headline image
AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer Treatments ↗
AstraZeneca to acquire Fusion Pharmaceuticals for $21.00 per share cash plus $3.00 per share CVR upon regulatory milestone achievement, marking a significant $2.4 billion deal. Enhancing cancer... 
Via Benzinga
News headline image
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
From AstraZeneca
Via Business Wire
News headline image
AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer ↗
AstraZeneca's latest analysis on Imfinzi plus chemotherapy followed by Imfinzi plus Lynparza in endometrial cancer. Improved secondary efficacy endpoints in patients with advanced or recurrent... 
Via Benzinga
News headline image
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
From AstraZeneca
Via Business Wire
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.